Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
暂无分享,去创建一个
D. Nieboer | M. Sosef | R. Valkema | E. Schoon | S. Meijer | G. Nieuwenhuijzen | K. Biermann | M. Luyer | J. V. van Lanschot | M. Roef | A. van der Gaast | M. I. van Berge Henegouwen | S. Lagarde | R. Bennink | B. Wijnhoven | M. Spaander | L. Oostenbrug | R. Riedl | S. Gisbertz | K. Krishnadath | S. Nikkessen | I. van Lijnschoten | B. Noordman | M. Doukas | B. J. van der Wilk | Lisanne K. A. Neijenhuis | Lisanne K A Neijenhuis | L. Neijenhuis | S. Meijer | Roel J. Bennink | Robert G. Riedl | Ineke van Lijnschoten | M. Spaander | M. Sosef | E. J. Schoon | J. van Lanschot | S. Lagarde
[1] E. Steyerberg,et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. , 2018, The Lancet. Oncology.
[2] J. Lagergren,et al. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS) , 2018, Annals of Surgical Oncology.
[3] E. Steyerberg,et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial , 2018, BMC Cancer.
[4] E. Steyerberg,et al. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] A. Chang,et al. Benchmarking Complications Associated with Esophagectomy , 2017, Annals of surgery.
[6] J. Ajani,et al. Final Results of NRG Oncology RTOG 0246: An Organ‐Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] E. Steyerberg,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.
[8] Arnulf H Hölscher,et al. International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). , 2015, Annals of surgery.
[9] E. Steyerberg,et al. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol , 2015, JMIR Research Protocols.
[10] Sung-Bae Kim,et al. Role of surgical resection in complete responders on FDG‐PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma , 2014, Journal of surgical oncology.
[11] C. Mariette,et al. Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study , 2013, Annals of surgery.
[12] J. Ajani,et al. Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation , 2013, Oncology.
[13] A. Ruol,et al. Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary? , 2013, Journal of Gastrointestinal Surgery.
[14] B. O'neill,et al. Targeting therapy for esophageal cancer in patients aged 70 and over. , 2013, Journal of geriatric oncology.
[15] J. Ajani,et al. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation , 2012, Oncology.
[16] E W Steyerberg,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.
[17] C. Castoro,et al. Systematic review of health-related quality of life after esophagectomy for esophageal cancer. , 2011, World journal of gastroenterology.
[18] Y. Doki,et al. Prognostic Value of Endoscopic Biopsy Findings After Induction Chemoradiotherapy With and Without Surgery for Esophageal Cancer , 2011, Annals of Surgery.
[19] J. Hagen,et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. , 2010, Journal of the American College of Surgeons.
[20] S. Meijer,et al. The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer , 2009, Annals of surgery.
[21] T. Djärv,et al. Predictors of postoperative quality of life after esophagectomy for cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Meijer,et al. Anti-β1 Integrin Antibody Reduces Surgery-Induced Adhesion of Colon Carcinoma Cells to Traumatized Peritoneal Surfaces , 2008, Annals of surgery.
[23] J. Ajani,et al. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. , 2007, International journal of radiation oncology, biology, physics.
[24] T. Conroy,et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Mats Lindblad,et al. Risk Factors for Complications After Esophageal Cancer Resection: A Prospective Population-Based Study in Sweden , 2006, Annals of surgery.
[26] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[27] Nils Lehmann,et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Sprangers,et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[30] Y. Tachimori,et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. , 2009, The Journal of thoracic and cardiovascular surgery.
[31] Peter D Siersema,et al. Esophageal cancer. , 2008, Gastroenterology clinics of North America.
[32] Ara A Vaporciyan,et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. , 2002, The Journal of thoracic and cardiovascular surgery.
[33] N. Gül,et al. Uva-dare (digital Academic Repository) Surgery-induced Reactive Oxygen Species Enhance Colon Carcinoma Cell Binding by Disrupting the Liver Endothelial Cell Lining Surgery-induced Reactive Oxygen Species Enhance Colon Carcinoma Cell Binding by Disrupting the Liver Endothelial Cell Lining , 2022 .
[34] M. Makuuchi,et al. The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.